- Home
- ALX vs SVRA Comparison
ALX vs SVRA Comparison
Compare ALX & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALX | SVRA |
|---|---|---|
| Founded | 1928 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1994 | 2009 |
Fundamental Metrics
Financial Performance| Metric | ALX | SVRA |
|---|---|---|
| Price | $231.30 | $5.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 74.9K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.50 | N/A |
| Revenue | ★ $213,183,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $42.40 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $189.05 | $1.89 |
| 52 Week High | $260.84 | $7.01 |
Technical Indicators
Market Signals| Indicator | ALX | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 40.47 |
| Support Level | $229.52 | $5.10 |
| Resistance Level | $235.65 | $6.06 |
| Average True Range (ATR) | 8.17 | 0.31 |
| MACD | -0.83 | -0.03 |
| Stochastic Oscillator | 30.57 | 6.42 |
Price Performance
Historical ComparisonAbout ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.